Allergan plc (NYSE:AGN) Shares Sold by Fjarde AP Fonden Fourth Swedish National Pension Fund
Fjarde AP Fonden Fourth Swedish National Pension Fund lowered its position in shares of Allergan plc (NYSE:AGN) by 2.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 91,308 shares of the company’s stock after selling 2,100 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Allergan were worth $16,171,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Wealth Quarterback LLC acquired a new stake in Allergan in the fourth quarter valued at $25,000. WASHINGTON TRUST Co purchased a new position in shares of Allergan in the 1st quarter valued at about $25,000. Golden State Wealth Management LLC acquired a new stake in shares of Allergan during the 1st quarter worth about $25,000. Paragon Capital Management LLC purchased a new stake in Allergan during the first quarter worth approximately $30,000. Finally, Princeton Global Asset Management LLC acquired a new position in Allergan in the fourth quarter valued at approximately $34,000. 83.91% of the stock is currently owned by hedge funds and other institutional investors.
Allergan stock remained flat at $$193.02 during mid-day trading on Friday. The company’s stock had a trading volume of 12,442,653 shares, compared to its average volume of 4,008,576. The stock has a fifty day moving average price of $185.22 and a 200-day moving average price of $187.00. Allergan plc has a 52 week low of $114.27 and a 52 week high of $202.21. The stock has a market capitalization of $63.50 billion, a price-to-earnings ratio of -12.07, a PEG ratio of 1.63 and a beta of 1.20. The company has a current ratio of 1.01, a quick ratio of 0.84 and a debt-to-equity ratio of 0.31.
AGN has been the subject of several recent analyst reports. ValuEngine upgraded shares of Allergan from a “sell” rating to a “hold” rating in a research report on Tuesday, March 24th. Cfra downgraded shares of Allergan from a “buy” rating to a “hold” rating in a research note on Wednesday, March 25th. Finally, SunTrust Banks lowered Allergan from a “buy” rating to a “hold” rating and raised their price objective for the stock from $191.00 to $193.00 in a report on Tuesday, April 21st. Fourteen research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $183.73.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Read More: Fundamental Analysis and Choosing Stocks
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.